Purpose: To test the hypothesis that poor brain tissue oxygenation (BtO 2 ) during the first 24 h of critical illness correlates with the proportion of time spent delirious. We also sought to define the physiological determinants of BtO 2 . Materials and methods: Adult patients admitted to the ICU within the previous 24 h were considered eligible for enrollment if they required mechanical ventilation, and/or vasopressor support. BtO 2 was measured using nearinfrared spectroscopy, for 24 h after enrollment. Hourly vital signs and clinically ordered arterial and central venous blood gases were collected throughout BtO 2 monitoring. Patients were screened daily for delirium with the confusion assessment method for the intensive care unit (CAM-ICU). Results: BtO 2 and the proportion of time spent delirious did not result in a significant correlation (p = 0.168). However, critically ill patients who spent the majority of their ICU stay delirious had significantly lower mean BtO 2 compared to non-delirious patients, (p = 0.017). BtO 2 correlated positively with central venous pO 2 (p = 0.00003) and hemoglobin concentration (p = 0.001). Logistic regression indicated that lower BtO 2 , higher narcotic doses and a history of alcohol abuse were independent risk factors for delirium. Conclusions: Poor cerebral oxygenation during the first 24 hours of critical illness contributes to the development of delirium. Trial registration: This trial is registered on clinicaltrials.gov (Identifier: NCT02344043), retrospectively registered January 8, 2015.
Introduction
Delirium is common during critical illness and manifests as an acute fluctuating change in mental status characterized by an altered level of consciousness or disorganized thinking [1] . Delirium has been associated with increased mortality, longer intensive care unit (ICU) length of stay and mechanical ventilation duration [2, 3] and long-term cognitive impairment [4] . Although the underlying etiology of delirium is unknown, neuropathological studies suggest that diffuse neuronal ischemia is common in critically ill patients, primarily affecting brain areas susceptible to hypoxic-ischemic injury such as watershed areas in the frontal cortex [5] . Therefore, poor cerebral perfusion may contribute to delirium. Reliable cerebral perfusion measurements during critical illness have only recently become available.
Near infrared spectroscopy (NIRS) is a non-invasive strategy to measure regional brain tissue oxygenation (BtO 2 ) [6] , and has been used as a surrogate marker for cerebral perfusion during cardiac surgery. In this clinical setting, low BtO 2 levels are associated with worse post-operative cognitive outcomes [7] . Low BtO 2 has also been associated with poor neurological outcomes in cardiac arrest survivors [8] . NIRS derived BtO 2 may serve as a marker and predictor of delirium. For example, in a small cohort of septic shock patients, lower BtO 2 was observed in delirious patients compared to non-delirious patients [9] . In another small sample of patients with septic shock, BtO 2 recordings over 72 h were lower in patients who spent the majority of their ICU stay delirious, relative to non-delirious patients [10] . Although poor perfusion may contribute to delirium, the association between BtO 2 and delirium requires further study.
Our study tested the hypothesis that poor cerebral oxygenation during the resuscitative phase (i.e. first 24-48 h) of critical illness is associated with the subsequent development of delirium throughout a patient's ICU stay. Additionally, we aimed to identify the physiological determinants related to BtO 2, such as hemodynamics and clinical measures of tissue oxygenation.
Materials and methods

Study design and participant recruitment
The Cerebral Oxygenation and Neurological outcomes FOllowing CriticAL illness (CONFOCAL) study (NCT02344043 clinicaltrials.gov) is a single-centre prospective observational study. The full protocol has been previously published [11] ; the acute neurological findings in this cohort are described herein. Adult patients (≥ 18 years) admitted to a 33-bed general medical/surgical and trauma ICU were eligible if they required mechanical ventilation with an expected duration N 24 h, and/or having shock of any etiology and were admitted to the ICU within the previous 24 h. Shock was defined by vasopressor requirement with infusions of: dopamine ≥ 7.5 mcg/kg/min, dobutamine ≥ 5 mcg/kg/min, norepinephrine ≥ 5 mcg/min, phenylephrine ≥ 75 mcg/min, epinephrine at any dose, milrinone at any dose (only in conjunction with another agent), or vasopressin ≥ 0.03 u/min (in conjunction with another agent) [4] . Participants were excluded if they had a life expectancy b 24 h, a pre-ICU diagnosis of cognitive dysfunction as indicated by their medical records on admission, or a primary central nervous system diagnosis (e.g. neurosurgical admission).
Data capture: demographics, BtO 2 , medications, and vital sign recording
At the time of enrollment, basic clinical and demographic information was collected. Thereafter, patients underwent BtO 2 monitoring with the FORESIGHT monitor (CASMED, Caster Medical, Canada). A single 5 cm sensor was placed in the centre of the patients' forehead and BtO 2 data was captured every 2 s for 24 h. The BtO 2 recordings were not revealed to the treating clinicians. Hourly physiological variables (e.g. blood pressure) were collected simultaneously. These BtO 2 and hourly physiological variables were then converted to mean values for statistical analysis. Sedative/analgesic medications administered during the first 24 h of critical illness either by continuous infusion or bolus doses were tallied and converted to "fentanyl equivalents" for narcotics, and "midazolam equivalents" for benzodiazepine medications [12] .
Delirium screening
Patients were assessed once daily for delirium throughout their ICU stay or (up to 30 days), using the confusion assessment method (CAM)-ICU [13] , which was administered by trained researchers. Patients were assigned to one of 3 pre-defined subgroups: 1) comatose (Richmond Agitation Sedation Scale; (RASS) −4 or −5) and not assessable for the ICU stay, 2) delirious for the majority (≥50%) of the ICU stay, or 3) non-delirious for the majority of the ICU stay. As comatose patients cannot be screened for delirium, we used the number of non-comatose days as the denominator in calculating the proportion of ICU stay spent either delirious or non-delirious. We have chosen to consider coma as a distinct entity, rather than an extreme of cognitive dysfunction. For example, a patient may be admitted with respiratory failure due to pneumonia and is mechanically ventilated with pharmacological paralysis/ heavy sedation, but would otherwise be neurologically intact if not for the iatrogenic coma. This contrasts significantly with the patient who has profound shock and remains comatose for the first 24 h despite aggressive resuscitation and little or no sedation. We feel that including the number of days a patient spends in this highly heterogeneous state would dilute any putative relationship between BtO 2 and delirium. ICU discharge was documented as the day the discharge was ordered, as delayed discharges occur due to lack of ward beds.
Data analysis
2.4.1. Sample size calculation and assessment of primary outcome
Our primary hypothesis was that there is a negative association between BtO 2 recordings and the proportion of ICU time spent delirious (i.e. days CAM-ICU positive). Our primary analysis used Spearman's correlation coefficient to test the correlation between the average BtO 2 during the first 24 h in the ICU and the proportion of ICU days with delirium. We used Spearman's rank correlation coefficient rather than Pearson's correlation coefficient, because the scatterplot of BtO 2 versus proportion of ICU days with delirium clearly showed the data was not normally distributed.
We enrolled 89 patients (i.e. at least 1 day of CAM-ICU screening) so that we would achieve approximately 80% power to detect a moderate correlation (ρ = 0.3; [14] ) using Spearman's rank correlation coefficient at a 2-sided alpha = 0.05. The actual power for a given correlation depends on the distribution of the two variables being correlated. For example, if the variables were distributed bivariate normally we would have about 78% power, while if the variables were distributed uniformly with BtO 2 ranging from 50 to 80 and proportion of delirium days ranging from 0 to 1, we would achieve 81% power (estimated using PASS software with 200,000 simulations [15] ).
Secondary outcomes-physiological variables and medications
A one-way between subjects analysis of variance (ANOVA) determined if mean BtO 2 measurements differed significantly between the three neurological states described above. Post hoc comparisons were performed using Tukey's HSD test. Spearman's rank correlation coefficients were conducted between mean BtO 2 recordings with mean hemodynamic/physiological parameters, that were collected during the 24 h recording period, for all enrolled patients, as these parameters were not normally distributed. The Kruskal-Wallis rank sum test was used to determine if there were significant differences in physiological variables, sedative medications, and narcotics, among delirious, non-delirious, and comatose patients. Dunn's Multiple Comparisons Test was used, with Bonferroni adjustment, when the Kruskal-Wallis rank sum test was significant. Correlations and between group differences were considered significant if p b 0.05. When the Bonferroni correction was applied, the corrected p value is stated.
Logistic regression
To determine if BtO 2 is an independent predictor of delirium, logistic regression was used to estimate the unadjusted effect of each individual predictor on having a majority of ICU days delirious (after excluding comatose days). The models provide odds ratios of having a majority of ICU days delirious with 95% confidence intervals and corresponding pvalues estimated by Wald's method. We fitted a multivariable model adjusting for the following covariates specified a priori [11] , as they were likely to be associated with delirium [3] : a history of hypertension, a history of alcohol abuse, total sedative dose (in midazolam equivalents), and total narcotic dose (in fentanyl equivalents). Due to the possibility of overfitting, we also provide a reduced model dropping covariates with p b 0.15 by backward selection. Statistical analysis was performed using R Software version 3.3.2 [16] and SAS version 9.4 software (https://www.sas.com).
Results
Patient characteristics
From March 2014-September 2016, 1155 patients were assessed for eligibility, and 104 were enrolled (Fig. 1 ). Patients were largely excluded because they were admitted with a primary neurological/neurosurgical diagnosis (n = 272), were N24 h post-ICU admission (n = 211), had an expected duration of mechanical ventilation b24 h (n = 206), or had a history of cognitive impairment (n = 106). One enrolled patient was identified as having a new ischemic stroke after inclusion and was therefore excluded. This sample had 19 patients (18%) that spent the majority (≥ 50%) of their ICU delirious, while 69 patients (67%) were non-delirious for the majority of their ICU stay. Fifteen patients (15%) remained comatose for their entire ICU stay (Table 1) . Most patients were intubated at enrollment (95%), and most were being treated with vasoactive agents (69%). The median length of ICU stay was 7 days (IQR, 4 to 13) and median ICU mortality was 28 (27%) ( Table 1) .
Relationship between BtO 2 and the proportion of ICU stay spent delirious
In order to quantify delirium, we used the proportion of time spent delirious as a continuous outcome variable, with mean BtO 2 during the 24 h of recording as the predictor. The correlation between mean BtO 2 recording and the proportion of time spent delirious was non-significant (ρ = −0.148, 95% CI, −0.345 to 0.063; p = 0.168) (Fig. 2A) . As our pilot data demonstrated that septic shock patients spending the majority of their ICU stay delirious have lower values of BtO 2 [10] , we planned an a priori assessment of the following subgroups: based on whether or not patients spent the majority of their ICU stay delirious, non-delirious; or comatose (i.e. RASS − 4 or −5) for the entirety of their ICU stay. The mean (±SD) BtO 2 was significantly higher in patients who were non-delirious, compared to delirious patients (69.4 ± 5.7 vs. 65.3 ± 5.4; p = 0.008). There was no significant difference in mean BtO 2 between comatose and delirious patients (p = 0.784), nor comatose and non-delirious patients (p = 0.199) (Fig. 2B) . Fig. 1 . CONSORT diagram demonstrating patient inclusion and exclusion during patient recruitment. CAM-ICU; confusion assessment method-intensive care unit.
Clinical and demographic differences between delirious and non-delirious patients
We compared the baseline demographics and clinical characteristics of the patients who were delirious or non-delirious during the majority of their ICU stay ( Table 1) . The groups were similar in terms of their baseline comorbidities, admitting diagnosis, and severity of illness on admission. Relative to non-delirious patients, the delirious group had a higher proportion of patients with a history of alcohol abuse (7/19 vs. 5/69, p = 0.003) ( Table 1) .
Sedative and analgesic medications administered during the 24 h period of BtO 2 recording
The mean total doses of fentanyl equivalents were significantly different among the three groups (p = 0.034). Delirious patients had significantly higher total doses of fentanyl equivalents, relative to nondelirious patients (p = 0.014) (Fig. 2C) . There was no significant difference in total fentanyl doses between comatose and delirious patients (p = 0.171), nor comatose and non-delirious patients (p = 0.978) (Fig. 2C) . The total dose of midazolam equivalents was not significantly different among the three groups (p = 0.24) (Fig. 2D) .
Hemodynamic parameters across all three neurological statuses
We compared the differences between mean vital sign recordings among patients who were comatose, delirious, or non-delirious for the majority of their ICU stay. The median MAP was the only variable significantly different among the three groups (p = 0.004). Comatose patients (69.6, IQR, 68.2 to 72.7) had significantly lower MAP relative to both non-delirious (75.1, IQR, 71.9 to 80.7, p = 0.002) and delirious patients (74.9, IQR, 71.4 to 81.0; p = 0.030) (Supplemental Fig. 1 ).
Physiological determinants of BtO 2
All patients were pooled together to assess the relationship between BtO 2 and hourly vital sign recordings. The only traditional vital sign that was statistically significant was peripheral oxygen saturation, which displayed a significant negative association with BtO 2 (ρ = − 0.341, 95% CI, −0.501 to −0.157; p = 0.0004) (Supplemental Fig. 2) . Furthermore, we assessed the relationship between BtO 2 and other physiological determinants of oxygen delivery by correlating BtO 2 with arterial and central venous blood samples. This analysis indicated that BtO 2 had a significant positive association with central venous pO 2 ( Fig. 3A; 95% CI, 0.334 to 0.728; p = 0.00003), but not arterial pO 2 ( Fig. 3B ; 95% CI, −0.381 to 0.049, p = 0.125). There was a significant positive association between BtO 2 and hemoglobin concentration ( Fig. 3C ; 95% CI, 0.147 to 0.506; p = 0.001).
3.7. BtO 2 , history of alcohol abuse, and narcotic dose may predict the subsequent development of delirium To determine whether or not BtO 2 was an independent risk factor for spending the majority of a patients' ICU stay delirious, logistic regression was performed ( Table 2 ). The univariate analysis demonstrated that increasing total dose of fentanyl equivalents and a history of alcohol abuse increased the odds of patients spending the majority of their ICU stay delirious, whereas increasing BtO 2 decreased these odds. Total midazolam dose and hypertension history did not significantly affect the odds of developing delirium. The full multivariable model estimate that after adjusting for fentanyl equivalents, midazolam equivalents, alcohol abuse and chronic hypertension, the odds of spending the majority of the ICU stay delirious is multiplied by 0.16 (i.e. decreasing the odds of being delirious) for each 10% increase in BtO 2 (95% CI, 0.05-0.56, p = 0.004). Removal of the one outlying patient with a BtO 2 value below 55 and delirium throughout their entire ICU stay did not meaningfully change the estimates (data not shown).
Discussion
The etiology of delirium appears to be multifactorial and prior studies have suggested that delirium is associated with the degree of multiorgan failure, inflammatory cytokines, microvascular damage, thrombosis, and impaired oxidative metabolism [17] [18] [19] . We propose that poor cerebral perfusion early in a patients' ICU stay also contributes to the risk of developing delirium. Empirical evidence that cerebral hypoperfusion contributes to the development of delirium is limited. This may be related to the difficulties in measuring cerebral perfusion in this population. However, previous research has indicated that reduced regional cerebral blood flow during delirium resolved after recovery from delirium using xenon-enhanced CT [20] . Our findings further support their hypothesis that poor cerebral perfusion contributes to the development of delirium, suggesting that optimizing BtO 2 may offer promising avenues of care during critical illness.
We looked specifically at differences in the administration of benzodiazepines and narcotics in our patient cohort, as these two medication classes may increase the risk of ICU delirium. Although there was no difference between the dose of midazolam equivalents administered to patients who spent the majority of their ICU stay delirious or non-delirious, delirious patients received a median narcotic dose that was almost 3-fold that of the non-delirious patients. Clinically, delirium may have been interpreted as pain, leading to the administration of higher doses. Conversely, the administration of narcotics may have led to deeper sedation, a potential confounder for positive CAM-ICU assessments. The underlying reason for administering higher narcotic doses will be pertinent metrics to analyze in future investigations.
Our data corroborates studies [3, 21, 22] describing alcohol abuse as an independent risk factor for the development of delirium. The reason for this association is unclear, but may extend beyond alcohol withdrawal. Alcohol abuse may place a patient at risk for nutritional deficiencies, or be a surrogate marker for other unknown risk factors for the development of delirium. In our study, many patients were delirium-free for most of their ICU stay with BtO 2 levels below the median. Almost none of these non-delirious patients with low BtO 2 had a history of alcohol abuse. In contrast, nearly half of the delirious patients with BtO 2 below the median had a history of alcohol abuse. This finding raises the possibility that individuals with a history of alcohol abuse may not have enough cognitive reserve to tolerate poor BtO 2 during critical illness.
Our study also sought to characterize the underlying determinants of BtO 2 during critical illness. Recently, NIRS derived BtO2 was demonstrated to be correlated with peripheral oxygen saturation, cardiac index, and MAP in a small cohort of patients with septic shock [23] . We found no consistent relationship between BtO 2 and either MAP or heart rate, possibly related to more heterogeneous groups of critically ill patients in our study. The weak negative correlation between peripheral oxygen saturation and BtO 2 may be related to the fact that peripheral oxygen saturation is derived from pulsatile (i.e. arterial) flow, whereas approximately 75% of the NIRS signal is derived from venous circulation [24, 25] . This is further supported by our finding of a positive correlation between BtO 2 and central venous O 2 (see also ref. [23] ).
The lack of correlation between BtO 2 and hemodynamic parameters (e.g. HR) could be related to the fact that the hourly vital sign recordings used for the correlations may not be representative of the overall signal [11, 26] . Alternatively, there could be considerable inter-individual variability in the manner in which BtO 2 correlates with hemodynamics. For example, cerebral autoregulatory reflexes ensure constant cerebral perfusion across a range of hemodynamic states, such that BtO 2 should not correlate with hemodynamic variables. A loss of autoregulation results in cerebral perfusion being directly reliant on hemodynamic states, thus leading to significant correlations between BtO 2 and hemodynamic parameters. Critically ill patients with severe sepsis have been shown to have impaired cerebral autoregulation during the first 24-48 h [27] . An assessment of cerebral autoregulation will be imperative in future studies designed to understand the relationship between BtO 2 and patient hemodynamics.
Study limitations
Our study is limited by the single centre design and small sample of patients who spent the majority of their ICU stay delirious. Due to the fluctuating course of delirium, future analysis may need to incorporate multiple daily CAM-ICU assessments (≥2). Furthermore, we were unable to fit a comprehensive model to explore the multifactorial nature of delirium, as well as adjust for relevant covariates. Furthermore, to further validate our logistic regression results, our models will need to be reconfirmed using a larger cohort of critically ill patients (e.g. multi-centre observational study) as this was strictly exploratory. In addition, the mean value of BtO 2 may not reflect individual variability. It is possible that a mean value (e.g. 70%) may be relatively 'ischemic' for one patient, while another patient may have adequate perfusion at the same mean. In addition, using data reduction techniques, such as mean/medians, may not be representative of the high-frequency BtO 2 signal. Despite these limitations however, we identified low BtO 2 as a novel marker associated with the development of delirium.
Conclusions
This study demonstrates that low BtO 2 is an independent risk factor for the subsequent development of delirium. Although delirium in the ICU is a complex phenomenon, this finding raises the possibility that future studies may lead to targeted strategies to optimize cerebral oxygenation during critical illness to prevent delirium.
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